During the corresponding time, Lumos Pharma Inc recorded a revenue increase by 10271.43 % year on year, sequentially revenue grew by 48.77 %. While revenue at the Lumos Pharma Inc 's corporate clients
Lumos Pharma Inc's Comment on Sales, Marketing and Customers
The company is developing LUM-201 for the treatment of a subset of Pediatric Growth Hormone Deficiency (PGHD) patients. This targets a market currently served by daily or weekly subcutaneous injection therapies for Growth Hormone Deficiency (GHD). The company's commercial strategy involves either establishing a specialty sales organization or partnering with third parties that have existing sales and distribution capabilities. Target customers include patients with rare disorders treated by specialists, healthcare providers, and third-party payors.
The company faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology firms marketing recombinant human growth hormone (rhGH) therapies, as well as academic and government research organizations. Current standard-of-care rhGH therapies include Norditropin® (Novo Nordisk), Humatrope® (Eli Lilly and Company), Nutropin-AQ® (F. Hoffman-La Roche Ltd./Genentech, Inc.), Genotropin® (Pfizer Inc.), Saizen® (Merck Serono S.A.), Tev-tropin® (Teva Pharmaceuticals Industries Ltd.), Omnitrope® (Sandoz GmbH), Valtropin® (LG Life Science and Biopartners GmbH), Zomacton® (Ferring Pharmaceuticals, Inc.), Skytrofa® (Ascendis Pharma), Nglena (OPCO Health, Inc., in collaboration with Pfizer), and Sogroya (Novo Nordisk).
Entities referenced across filings include Ascendis Pharma, Eli Lilly and Company, F. Hoffman-La Roche Ltd., Ferring Pharmaceuticals, Inc., Genentech, Inc., LG Life Science and Biopartners GmbH, Merck Serono S.A., Novo Nordisk A/S, OPCO Health, Inc., Pfizer Inc., Sandoz GmbH, and Teva Pharmaceuticals Industries Ltd.
Austin, Texas, September 5, 2024 Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for rare diseases, is poised to make a significant impact at the upcoming XXXI Meeting of the Latin American Society of Paediatric Endocrinology (SLEP 2024). The company recently announced that an updated analysis of its data from Phase 2 clinical trials OraGrowtH210 and OraGrowtH212 has been accepted for presentation during this prestigious medical meeting, set to take place from September 11-14, 2024, in Santiago, Chile.The conferences such as SLEP play a crucial role in fostering collaboration among medical professionals and researchers ...
Lumos Pharma Announces s Accepted for Presentation at ENDO 2024Lumos Pharma, a clinical stage biopharmaceutical company dedicated to developing therapeutics for rare diseases, has recently announced that new data analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO) in Boston, MA. The conference is scheduled to take place from June 1-4, 2024.Lumos Pharma focuses on addressing the unmet medical needs of patients with rare diseases, particularly those affecting the endocrine system. The company s Phase 2 clinical trials, OraGrowtH210 and OraGrowtH212, evaluate the efficacy and safety ...
Lumos Pharma Inc’s Comment on Sales, Marketing and Customers
The company is developing LUM-201 for the treatment of a subset of Pediatric Growth Hormone Deficiency (PGHD) patients. This targets a market currently served by daily or weekly subcutaneous injection therapies for Growth Hormone Deficiency (GHD). The company's commercial strategy involves either establishing a specialty sales organization or partnering with third parties that have existing sales and distribution capabilities. Target customers include patients with rare disorders treated by specialists, healthcare providers, and third-party payors.
The company faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology firms marketing recombinant human growth hormone (rhGH) therapies, as well as academic and government research organizations. Current standard-of-care rhGH therapies include Norditropin® (Novo Nordisk), Humatrope® (Eli Lilly and Company), Nutropin-AQ® (F. Hoffman-La Roche Ltd./Genentech, Inc.), Genotropin® (Pfizer Inc.), Saizen® (Merck Serono S.A.), Tev-tropin® (Teva Pharmaceuticals Industries Ltd.), Omnitrope® (Sandoz GmbH), Valtropin® (LG Life Science and Biopartners GmbH), Zomacton® (Ferring Pharmaceuticals, Inc.), Skytrofa® (Ascendis Pharma), Nglena (OPCO Health, Inc., in collaboration with Pfizer), and Sogroya (Novo Nordisk).
Entities referenced across filings include Ascendis Pharma, Eli Lilly and Company, F. Hoffman-La Roche Ltd., Ferring Pharmaceuticals, Inc., Genentech, Inc., LG Life Science and Biopartners GmbH, Merck Serono S.A., Novo Nordisk A/S, OPCO Health, Inc., Pfizer Inc., Sandoz GmbH, and Teva Pharmaceuticals Industries Ltd.
Sources:
Lumos Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lumos Pharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lumos Pharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
